Cerecor gets FDA fast track designation for CERC-802

Cerecor (NASDAQ:CERC) received FDA fast track designation for CERC-802 for the treatment of mannose-phosphate isomerase deficiency, also known as CDG-1b.

CDG-1b is a rare genetic disease that impacts carbohydrate metabolism, specifically protein glycosylation. CERC-802, an ultra-pure formulation of D-mannose, is designed to provide CDG-1b patients with the substrates required for normal protein glycosylation.

“We believe that the granting of fast track designation for CERC-802 is another crucial step in the development of a potential treatment for this ultra-rare condition,” Simon Pedder, executive chairman of Cerecor’s board, said in a statement.

“We continue to work closely with the FDA to advance this development program forward expeditiously. We’re currently collecting retrospective data through the CDG FIRST trial to support an NDA for a much-needed therapy,” he added.

The FDA previously granted CERC-802 orphan drug and rare pediatric disease designations, which makes Cerecor eligible to receive a priority review voucher upon NDA approval.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.